|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Steeg PS: Tumor metastasis: Mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Steeg PS: Cancer: Micromanagement of
metastasis. Nature. 449:671–673. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eccles SA and Welch DR: Metastasis: Recent
discoveries and novel treatment strategies. Lancet. 369:1742–1757.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells-perspectives on current status and future directions:
AACR workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bertolini G, Roz L, Perego P, Tortoreto M,
Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S,
et al: Highly tumorigenic lung cancer CD133+ cells display
stem-like features and are spared by cisplatin treatment. Proc Natl
Acad Sci USA. 106:16281–16286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Creighton CJ, Li X, Landis M, Dixon JM,
Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A,
Herschkowitz JI, et al: Residual breast cancers after conventional
therapy display mesenchymal as well as tumor-initiating features.
Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li X, Lewis MT, Huang J, Gutierrez C,
Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC,
et al: Intrinsic resistance of tumorigenic breast cancer cells to
chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Phillips TM, McBride WH and Pajonk F: The
response of CD24(−/low)/CD44+ breast cancer-initiating cells to
radiation. J Natl Cancer Inst. 98:1777–1785. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abraham BK, Fritz P, McClellan M,
Hauptvogel P, Athelogou M and Brauch H: Prevalence of
CD44+/CD24-/low cells in breast cancer may not be associated with
clinical outcome but may favor distant metastasis. Clin Cancer Res.
11:1154–1159. 2005.PubMed/NCBI
|
|
11
|
White N, Butler PE and Burnstock G: Human
melanomas express functional P2X(7) receptors. Cell Tissue Res.
321:411–418. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schafer R, Sedehizade F, Welte T and
Reiser G: ATP-and UTP-activated P2Y receptors differently regulate
proliferation of human lung epithelial tumor cells. Am J Physiol
Lung Cell Mol Physiol. 285:L376–L385. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shabbir M, Ryten M, Thompson C,
Mikhailidis D and Burnstock G: Purinergic receptor-mediated effects
of ATP in high-grade bladder cancer. BJU Int. 101:106–112.
2008.PubMed/NCBI
|
|
14
|
Janssens R and Boeynaems JM: Effects of
extracellular nucleotides and nucleosides on prostate carcinoma
cells. Br J Pharmacol. 132:536–546. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pellegatti P, Raffaghello L, Bianchi G,
Piccardi F, Pistoia V and Di Virgilio F: Increased level of
extracellular ATP at tumor sites: In vivo imaging with plasma
membrane luciferase. PLoS One. 3:e25992008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin H, Eun SY, Lee JS, Park SW, Lee JH,
Chang KC and Kim HJ: P2Y2 receptor activation by nucleotides
released from highly metastatic breast cancer cells increases tumor
growth and invasion via crosstalk with endothelial cells. Breast
Cancer Res. 16:R772014. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Joo YN, Jin H, Eun SY, Park SW, Chang KC
and Kim HJ: P2Y2R activation by nucleotides released from the
highly metastatic breast cancer cell MDA-MB-231 contributes to
pre-metastatic niche formation by mediating lysyl oxidase
secretion, collagen crosslinking, and monocyte recruitment.
Oncotarget. 5:9322–9334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin H, Ko YS and Kim HJ: P2Y2R-mediated
inflammasome activation is involved in tumor progression in breast
cancer cells and in radiotherapy-resistant breast cancer. Int J
Oncol. 53:1953–1966. 2018.PubMed/NCBI
|
|
19
|
Ko YS, Jin H, Lee JS, Park SW, Chang KC,
Kang KM, Jeong BK and Kim HJ: Radioresistant breast cancer cells
exhibit increased resistance to chemotherapy and enhanced invasive
properties due to cancer stem cells. Oncol Rep. 40:3752–3762.
2018.PubMed/NCBI
|
|
20
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in propagation of tumorigenic breast cancer cells
with stem/progenitor cell properties. Cancer Res. 65:5506–5511.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koo BS, Lee SH, Kim JM, Huang S, Kim SH,
Rho YS, Bae WJ, Kang HJ, Kim YS, Moon JH and Lim YC: Oct4 is a
critical regulator of stemness in head and neck squamous carcinoma
cells. Oncogene. 34:2317–2324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsai YH, VanDussen KL, Sawey ET, Wade AW,
Kasper C, Rakshit S, Bhatt RG, Stoeck A, Maillard I, Crawford HC,
et al: ADAM10 regulates Notch function in intestinal stem cells of
mice. Gastroenterology. 147:822–834.e13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanei T, Morimoto K, Shimazu K, Kim SJ,
Tanji Y, Taguchi T, Tamaki Y and Noguchi S: Association of breast
cancer stem cells identified by aldehyde dehydrogenase 1 expression
with resistance to sequential Paclitaxel and epirubicin-based
chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morimoto K, Kim SJ, Tanei T, Shimazu K,
Tanji Y, Taguchi T, Tamaki Y, Terada N and Noguchi S: Stem cell
marker aldehyde dehydrogenase 1-positive breast cancers are
characterized by negative estrogen receptor, positive human
epidermal growth factor receptor type 2, and high Ki67 expression.
Cancer Sci. 100:1062–1068. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Charafe-Jauffret E, Ginestier C, Iovino F,
Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci
F, Jacquemier J, et al: Aldehyde dehydrogenase 1-positive cancer
stem cells mediate metastasis and poor clinical outcome in
inflammatory breast cancer. Clin Cancer Res. 16:45–55. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Resetkova E, Reis-Filho JS, Jain RK, Mehta
R, Thorat MA, Nakshatri H and Badve S: Prognostic impact of ALDH1
in breast cancer: A story of stem cells and tumor microenvironment.
Breast Cancer Res Treat. 123:97–108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang EH, Hynes MJ, Zhang T, Ginestier C,
Dontu G, Appelman H, Fields JZ, Wicha MS and Boman BM: Aldehyde
dehydrogenase 1 is a marker for normal and malignant human colonic
stem cells (SC) and tracks SC overpopulation during colon
tumorigenesis. Cancer Res. 69:3382–3389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deng S, Yang X, Lassus H, Liang S, Kaur S,
Ye Q, Li C, Wang LP, Roby KF, Orsulic S, et al: Distinct expression
levels and patterns of stem cell marker, aldehyde dehydrogenase
isoform 1 (ALDH1), in human epithelial cancers. PLoS One.
5:e102772010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ciccone V, Terzuoli E, Donnini S,
Giachetti A, Morbidelli L and Ziche M: Stemness marker ALDH1A1
promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF
signalling in MCF-7 breast cancer cells. J Exp Clin Cancer Res.
37:3112018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parr C, Watkins G and Jiang WG: The
possible correlation of Notch-1 and Notch-2 with clinical outcome
and tumour clinicopathological parameters in human breast cancer.
Int J Mol Med. 14:779–786. 2004.PubMed/NCBI
|
|
33
|
Zardawi SJ, Zardawi I, McNeil CM, Millar
EK, McLeod D, Morey AL, Crea P, Murphy NC, Pinese M, Lopez-Knowles
E, et al: High Notch1 protein expression is an early event in
breast cancer development and is associated with the HER-2
molecular subtype. Histopathology. 56:286–296. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rizzo P, Miao H, D'Souza G, Osipo C, Song
LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, et al:
Cross-talk between notch and the estrogen receptor in breast cancer
suggests novel therapeutic approaches. Cancer Res. 68:5226–5235.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gallahan D and Callahan R: Mammary
tumorigenesis in feral mice: Identification of a new int locus in
mouse mammary tumor virus (Czech II)-induced mammary tumors. J
Virol. 61:66–74. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Smith GH, Gallahan D, Diella F, Jhappan C,
Merlino G and Callahan R: Constitutive expression of a truncated
INT3 gene in mouse mammary epithelium impairs differentiation and
functional development. Cell Growth Differ. 6:563–577.
1995.PubMed/NCBI
|
|
37
|
Uyttendaele H, Soriano JV, Montesano R and
Kitajewski J: Notch4 and Wnt-1 proteins function to regulate
branching morphogenesis of mammary epithelial cells in an opposing
fashion. Dev Biol. 196:204–217. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weijzen S, Rizzo P, Braid M, Vaishnav R,
Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC,
et al: Activation of Notch-1 signaling maintains the neoplastic
phenotype in human Ras-transformed cells. Nat Med. 8:979–986. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang JW, Wei XL, Dou XW, Huang WH, Du CW
and Zhang GJ: The association between Notch4 expression, and
clinicopathological characteristics and clinical outcomes in
patients with breast cancer. Oncol Lett. 15:8749–8755.
2018.PubMed/NCBI
|
|
40
|
Marhaba R and Zöller M: CD44 in cancer
progression: Adhesion, migration and growth regulation. J Mol
Histol. 35:211–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Orian-Rousseau V: CD44, a therapeutic
target for metastasising tumours. Eur J Cancer. 46:1271–1277. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zöller M: CD44: Can a cancer-initiating
cell profit from an abundantly expressed molecule? Nat Rev Cancer.
11:254–267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Marotta LL, Almendro V, Marusyk A,
Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ,
Choudhury SA, Maruyama R, et al: The JAK2/STAT3 signaling pathway
is required for growth of CD44+CD24− stem
cell-like breast cancer cells in human tumors. J Clin Invest.
121:2723–2735. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tan Q, Wang H, Hu Y, Hu M, Li X,
Aodengqimuge, Ma Y, Wei C and Song L: Src/STAT3-dependent heme
oxygenase-1 induction mediates chemoresistance of breast cancer
cells to doxorubicin by promoting autophagy. Cancer Sci.
106:1023–1032. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bonner JA, Trummell HQ, Willey CD, Plants
BA and Raisch KP: Inhibition of STAT-3 results in
radiosensitization of human squamous cell carcinoma. Radiother
Oncol. 92:339–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ling GQ, Chen DB, Wang BQ and Zhang LS:
Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in
human breast cancer cell lines. Oncol Lett. 4:1264–1268. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y,
Cao X, Ling EA and Hao A: Oct4 is expressed in human gliomas and
promotes colony formation in glioma cells. Glia. 57:724–733. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Matsuoka J, Yashiro M, Sakurai K, Kubo N,
Tanaka H, Muguruma K, Sawada T, Ohira M and Hirakawa K: Role of the
stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J
Surg Res. 174:130–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tai MH, Chang CC, Kiupel M, Webster JD,
Olson LK and Trosko JE: Oct4 expression in adult human stem cells:
Evidence in support of the stem cell theory of carcinogenesis.
Carcinogenesis. 26:495–502. 2005. View Article : Google Scholar : PubMed/NCBI
|
